Sofosbuvir and velpatasvir (Epclusa) resistance management

There are no data on the persistence of sofosbuvir and velpatasvir (Epclusa). In most patients, NS5A RASs observed when administered with other NS5A inhibitors persisted for more than 1 year. The long-term clinical impact of the emergence or persistence of viruses in RASs containing sofosbuvir or velpatasvir is unknown. Treatment was well tolerated in an open, multicenter study evaluating the sofosbuvir-velpatasvir combination in treatment-naïve or genotyped participants.

Adverse events were similar to those observed in adults in the Phase 3 study, with the most common adverse events in children aged 6 to 11 years being headache (15% and 29%), fatigue (12% and 22%), nausea (7% and 17%), vomiting (16% and 9%), and cough (15% and 9%). Overall, 94% of retreatment patients achieved SVR. All patients treated with the combination of sofosbuvir and velpatasvir + ribavirin achieved SVR (100%), and the presence of RASs before retreatment did not affect the achievement of SVR. However, everyone’s physique is different and their resistance to drugs is also different. If you feel unwell, please inform your doctor in time.

The original drug of sofosbuvir and velpatasvir has been launched in China and has entered the scope of Class B medical insurance. The domestic trade name is protonsa, and the specification (400mg+100mg)*28 tablets is about 4,000 yuan per box. The original drug of sofosbuvir and velpatasvir has also been launched overseas. There are also generic drugs of sofosbuvir and velpatasvir produced in other countries. The price of the specification (400mg+100mg)*28 tablets produced by Bangladesh Everest Pharmaceutical Factory is around 850 yuan per box (the price may fluctuate due to the exchange rate). The generic drugs produced abroad are basically the same as the original drugs at home and abroad.